If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Data validate Femara alone for five years following hormone-receptor positive breast cancer surgery as an optimal first treatment vs. tamoxifen in postmenopausal women Results show long-term superiority of Femara in improving disease-free survival (P=0….
Biopharmaceuticals, Onology
Novartis, Femara, letrozole, breast cancer, tamoxifen
Posts from ‘August, 2009’
Results In’The New England Journal Of Medicine’ Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Long Beach PET Imaging Center Completes Installation of New State-of-the-Art PET/CT Scanner
Siemens Biograph PET/CT First in Area Cuts Scan Time in Half and Offers Enhanced Lesion Detection LONG BEACH, Calif.–(HSMN NewsFeed)–Long Beach PET Imaging Center, a leading diagnostic imaging center in the Long Beach, Calif.-area, announced today …
Devices, Radiology, Oncology
Siemens Healthcare, Biograph PET/CT, PET/CT
EDAP Receives U.S. FDA 510(k) Approval for Sonolith I-Sys
Novel, Innovative and Robotized Next-Generation Lithotripsy Device to Enter U.S. Market LYON, France, Aug. 19, 2009 –(HSMN NewsFeed) — EDAP TMS SA (Nasdaq:EDAP ), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug…
Devices, Urology, FDA
EDAP TMS, Sonolith I-Sys, lithotripsy, high-intensity focused ultrasound
Smith and Nephew Takes Single Injection PMA to Next Stage
RALEIGH and DURHAM, N.C., Aug. 19 (HSMN NewsFeed) — Smith & Nephew (NYSE: SNN ; LSE: SN ) Biologics & Spine is proceeding to the next stage in the approval process for the U.S. launch of DUROLANE(R) Single Injection, Stabilized Hyaluronic Acid. Repre…
Devices, Orthopaedic, FDA
Smith & Nephew, Q-Med, DUROLANE, Hyaluronic Acid
Par Pharmaceutical and Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
Par to Begin Shipping Clonidine TDS in the Near Future WOODCLIFF LAKE, N.J., Aug. 18 (HSMN NewsFeed) — Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that its licensing partner, Aveva Drug Delivery Systems, has received final approva…
Biopharmaceuticals, Generics, FDA
Par Medical, Aveva Drug Delivery Systems, clonidine transdermal system
Viztek Relocates to Raleigh
Debuts Enhanced Data Storage Services Raleigh, NC, Aug 18–(HSMN NewsFeed)–Viztek, the radiology solution provider, is moving its corporate headquarters to Raleigh, N.C., effective August 15. The spacious, new 80,000 square foot facility will support s…
Devices
Viztek
CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
ATLANTA, Aug. 18 (HSMN NewsFeed) — CryoLife, Inc., (NYSE: CRY ) an implantable biological clinical device and cardiovascular tissue processing company, today announced the first 3 implantations of the CryoPatch(R) SG pulmonary human cardiac patch sin…
Devices, Cardiology
CryoLife, CryoPatch, SynerGraft, cardiac patch
Abbott Announces Partnership with Velcera to Bring New Pain Medication for Dogs to Market
ABBOTT PARK, Ill., Aug. Eighteen (HSMN NewsFeed) — Abbott (NYSE: ABT ) announced today they have partnered with Velcera, Inc., a specialty pharma company focused on pet health, to market the first canine pain management product delivered in a transmuc…
Biopharmaceuticals, Drug Delivery
Abbott, Velcera, meloxicam, Promist , transmucosal
MAQUET Cardiovascular Launches VASOVISION Endoscopic Visualization System to Further Advance Vessel Harvest During Coronary Bypass Surgery
New Goggle-Based, Heads-Up Display System Designed to Aid Minimally-Invasive Vein Harvesting Methods WAYNE, N.J., Aug. 17 (HSMN NewsFeed) — MAQUET Cardiovascular LLC today announced the introduction of the VASOVISION Endoscopic Visualization System, …
Devices, Cardiology
MAQUET Cardiovascular, VASOVISION, Endoscopic Visualization
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
More than 2,000 XIENCE V Patients May Also Be Eligible to Join Industry-Wide Trial Studying Optimal Duration of Dual Anti-Platelet Therapy ABBOTT PARK, Ill., Aug. 13 (HSMN NewsFeed) — Abbott (NYSE: ABT ) today announced the expansion of the company’s…
Devices, Interventional Cardiology
Abbott, XIENCE V, Everolimus, drug eluting stent, anti-platelet
